Endexx launches adaptive clinical study of CBD capsule to treat neuropathic pain

20th April 2016 (Last Updated April 20th, 2016 18:30)

Hemp phyto-nutrients and nutritional products provider Endexx has started a doctor-supervised, adaptive clinical study to test the efficacy of its proprietary CBD capsule to treat patients suffering from neuropathic pain.

Hemp phyto-nutrients and nutritional products provider Endexx has started a doctor-supervised, adaptive clinical study to test the efficacy of its proprietary CBD capsule to treat patients suffering from neuropathic pain.

The one month study will enrol 20 patients in four groups and will use CBD enriched capsules to evaluate neuropathic pain reduction.

The proprietary formulations of CBD are pharmacist formulated and manufactured capsules, which include a dual pack as a day and night formula with cannabidiol as its primary active ingredient.

During the study, each patient will be given two capsules a day with results to be monitored.

At the end of the study, findings will be subjected to an independent peer review board.

"I also believe that in a capsule form, patients will be more compliant and have better results."

The study is an extension of the work conducted by Daniel Kiddy with his patients and a follow-up of Daniel Brandwein's research that demonstrated an average pain reduction after two weeks of usage from seven to eight down to three to four on a pain scale of one to ten, using four to five drops of CBD-rich hemp oil twice a day.

Brandwein said: "I am very excited about the upcoming new trial where we can follow the information even closer.

"I also believe that in a capsule form, patients will be more compliant and have better results.

"In some cases, my patients have decreased and discontinued their usage of Neurontin and Gabapentin."

Endexx currently has two technology products and services launched in 2014 - M3hub and Autospense.

Both the products provide solutions to support regulatory compliance and accountability through 'seed to sale' inventory management and tracking.

Endexx CEO Todd Davis said: "Endexx has defined two key market pathways for its CBD initiative: the consumer market for wellness and nutrition and the therapeutic and nutraceutical markets.

"Through the consumer market we are targeting the 'Platinum' age 40+ demographic seeking prolonged wellness, improved quality of life and the extension of an active lifestyle.

"Our phyto-cannabinoids-rich (PCR) products with cannabidiol from industrial hemp have proven to significantly enhance overall wellness and improve physical and mental condition. On the therapeutic side, we have been formulating and testing CBD-infused products with certified compound pharmacists and physicians in a medical environment."